NCT03309241View on ClinicalTrials.gov

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

February 21, 2018

Study Completion Date

March 22, 2018

Conditions
Healthy Subjects
Interventions
DRUG

PF-06882961

Single Ascending Doses of PF-06882961 from 3mg to TBD mg.

OTHER

Placebo

Placebo Single Dose

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03309241 - First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects | Biotech Hunter | Biotech Hunter